XTL Biopharmaceuticals Lt... (XTLB)
NASDAQ: XTLB
· Real-Time Price · USD
1.33
-0.09 (-6.34%)
At close: Aug 15, 2025, 1:40 PM
1.41
6.02%
After-hours: Aug 15, 2025, 04:00 PM EDT
XTL Biopharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 289K | 162K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 332K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -43K | 162K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -812K | -764K | -421K | -175K | -200K | -151K | -163K | -251K | -225K | -204K | -202K | -249K | -286K | -442K | -535K | -232K |
Interest Income | 2K | 13K | 9K | 10K | 126K | 9K | 9K | 12K | n/a | n/a | 5K | 3K | n/a | n/a | 5K | n/a |
Pretax Income | -385K | -553K | -704K | 485K | -284K | -215K | -364K | -919K | -748K | -821K | -285K | 506K | 2.1M | -510K | -865K | 286K |
Net Income | -255K | -553K | -704K | 485K | -284K | -215K | -364K | -919K | -748K | -821K | -285K | 506K | 2.1M | -510K | -865K | 286K |
Selling & General & Admin | 706K | 756K | 415K | 169K | 194K | 145K | 157K | 238K | 219K | 201K | 187K | 243K | 280K | 424K | 517K | 220K |
Research & Development | 32K | 54K | 6K | 6K | 6K | 6K | 6K | 13K | 6K | 3K | 15K | 6K | 6K | 18K | 18K | 12K |
Other Expenses | 31K | 116K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 769K | 926K | 421K | 175K | 200K | 151K | 163K | 251K | 225K | 204K | 202K | 249K | 286K | 442K | 535K | 232K |
Interest Expense | n/a | 93K | 13K | 16K | n/a | 28K | 32K | 25K | n/a | n/a | 11K | 9K | n/a | n/a | 14K | n/a |
Selling & Marketing Expenses | -106K | 284K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.1M | 926K | 421K | 175K | 200K | 151K | 163K | 251K | 225K | 204K | 202K | 249K | 286K | 442K | 535K | 232K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -9K | 6K | 9K | n/a |
Shares Outstanding (Basic) | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.28M | 5.28M | 5.27M |
Shares Outstanding (Diluted) | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.45M | 5.77M | 5.38M | 5.28M | 5.27M |
EPS (Basic) | -0.05 | -0.1 | -0.13 | 0.09 | -0.05 | -0.04 | -0.07 | -0.17 | -0.14 | -0.15 | -0.05 | 0.09 | 0.40 | -0.1 | -0.16 | 0.05 |
EPS (Diluted) | -0.05 | -0.1 | -0.13 | 0.09 | -0.05 | -0.04 | -0.07 | -0.17 | -0.14 | -0.15 | -0.05 | 0.09 | 0.37 | -0.09 | -0.16 | 0.05 |
EBITDA | -479K | -460K | -691K | 485K | -199.75K | -142K | -154K | -239K | -224.75K | -269K | -197K | -248.75K | -285.75K | -209.75K | -530K | -231.75K |
EBIT | -479K | -460K | -691K | 501K | -284K | -187K | -332K | -894K | -225K | -896K | -274K | 515K | -286K | 399K | -1.14M | -232K |
Depreciation & Amortization | n/a | 304K | -270K | 660K | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 |